Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF) (2016 - 2025)

Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 22.06% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $25.1 million, up 28.19%, while the annual FY2025 figure was $23.9 million, 28.68% up from the prior year.
  • Depreciation & Amortization (CF) reached $6.4 million in Q4 2025 per ARWR's latest filing, roughly flat from $6.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.4 million in Q4 2025 to a low of $1.9 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.9 million, with a median of $3.6 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): grew 2.89% in 2023, then skyrocketed 69.54% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.6 million in 2021, then grew by 4.51% to $2.7 million in 2022, then soared by 58.53% to $4.3 million in 2023, then rose by 22.8% to $5.2 million in 2024, then rose by 22.06% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Depreciation & Amortization (CF) are $6.4 million (Q4 2025), $6.4 million (Q3 2025), and $6.2 million (Q2 2025).